Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression

Haoyang Liu; Junru Chen; Qiyu Zhu; Haolin Liu; Yeechun Chuang; Mengni Zhang; Guangxi Sun; Hao Zeng

doi:10.1002/mco2.70427

MedComm ›› 2025, Vol. 6 ›› Issue (10) : e70427 DOI: 10.1002/mco2.70427

LETTER

Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression

Author information +

History +

PDF

Cite this article

Download citation ▾

Haoyang Liu, Junru Chen, Qiyu Zhu, Haolin Liu, Yeechun Chuang, Mengni Zhang, Guangxi Sun, Hao Zeng. Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression. MedComm, 2025, 6(10): e70427 DOI:10.1002/mco2.70427

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	X. Tan, Z. Liu, T. Cai, et al., “Prognostic Significance of HER2 Expression in Patients With Bacillus Calmette-Guérin-Exposed Non-Muscle-Invasive Bladder Cancer,” European Urology Oncology 7, no. 4 (2024): 760-769.

[2]	X. Hong, X. Chen, H. Wang, et al., “A HER2-Targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety With Intravesical Instillation in Preclinical Models of Bladder Cancer,” Advanced Science 10, no. 32 (2023): e2302377.

[3]

X. Sheng, L. Wang, Z. He, et al., “Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials,” Journal of Clinical Oncology 42, no. 12 (2024): 1391-1402.

[4]	F. C. de Jong, T. D. Laajala, R. F. Hoedemaeker, et al., “Non-Muscle-Invasive Bladder Cancer Molecular Subtypes Predict Differential Response to Intravesical Bacillus Calmette-Guérin,” Science Translational Medicine 15, no. 697 (2023): eabn4118.

[5]	C. Pettenati and M. A. Ingersoll, “Mechanisms of BCG Immunotherapy and Its Outlook for Bladder Cancer,” Nature Reviews Urology 15, no. 10 (2018): 615-625.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.